C:\Program Files\Stnexp\Queries\3.str





chain nodes :
1 2 3 4 7 8 9 10 11 12 13 14 15 16 17 18 19 26 27 28 29 33 42 49
50 51 52 53 54
ring nodes :
5 6 20 21 22 23 24 25 30 31 32 34 35 36 37 38 39 40 41 43 44 45 46
47 48
chain bonds :
1-2 1-49 1-54 2-3 3-4 3-46 4-5 4-42 6-7 7-8 7-33 8-9 9-10 9-29 10-11 10-28
11-12 11-27 12-13 13-14 14-15 14-26 15-16 16-17 16-20 17-18 17-19 29-30 49-50
50-51 51-52 51-53
ring bonds :
5-6 5-36 6-34 20-25 20-21 21-22 22-23 23-24 24-25 30-31 30-32 31-32 34-35
35-36 35-37 35-39 37-38 38-41 39-40 40-41 43-48 43-44 44-45 45-46 46-47 47-48
exact/norm bonds :
1-2 1-49 1-54 2-3 4-5 4-42 5-6 5-36 6-34 7-8 7-33 8-9 10-28 11-12 11-27
12-13 14-15 14-26 15-16 30-31 30-32 31-32 34-35 35-36 35-37 35-39 37-38 38-41
39-40 40-41 43-48 43-44 44-45 45-46 46-47 47-48 49-50
exact bonds :
3-4 3-46 6-7 9-10 9-29 10-11 13-14 16-17 16-20 29-30 50-51 51-52 51-53
normalized bonds :
17-18 17-19 20-25 20-21 21-22 22-23 23-24 24-25

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:Atom 31:Atom 32:Atom 33:CLASS 34:Atom 35:Atom 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:Atom 42:CLASS 43:Atom 44:Atom 45:Atom 46:Atom 47:Atom
48:Atom 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 54:CLASS

16/09/200315:47Print selected from Online session

d 19 bib ab hitstr 1,2

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:591204 CAPLUS
DN 139:149928
TI Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
IN Saksena, Anil K.; Girijavallabhn, Viyyoor M.; Lovey, Raymond G.; Jao, Edwin; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-yau; Liu, Yi-tsung; Zhu, Zhaoning; Njoroge, George F.; Arasappan, Ashok; Parekh, Tejal; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Wong, Jesse K.; Nair, Latha G.
PA Schering Corporation, USA; Corvas International, Inc.
SO PCT Int. Appl., 633 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062265	A2	20030731	WO 2003-US1430	20030116

PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-52386 A 20020118
OS MARPAT 139:149928
AB The invention discloses novel peptides I [Y is alkyl, alkylaryl, heteroalkyl, heteroaryl, aryl- or alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino, or heterocycloalkylamino; R1 is acyl; Z is selected from O, N, CH or CR; R, R2-R4 are H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halo, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; W, Q, G, J, L, M independently may be present or absent; W is CO, CS, C(:N-CN), or SO2; Q is CH, N, P, alkylidene, O, NR, S, or SO2; A is O, CH, alkylidene, NR, S, SO2, or a bond; E is CH, N, alkylidene, or a double bond; G is alkylidene; J is alkylidene, SO2, NH, NR, or O; L is CH, CR, O, S, or NR; M is O, NR, S, SO2, or alkylidene (with provisos)] which have HCV protease inhibitory activity as well as methods for prepg. such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease. Thus, peptide II was prepd. and showed Ki = 1-100 nM (category A) in the HCV continuous assay.
IT **394721-12-1P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)
(prepn. of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394721-12-1 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(3S)-6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:90062 CAPLUS
DN 136:167698
TI Preparation of peptides as NS3-serine protease inhibitors of hepatitis C virus
IN Saksena, Anil K.; Girijavallabhan, Viyyoor Moopil; Lovey, Raymond G.; Jao, Edwin E.; Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan; Pike, Russell E.; Bogen, Stephane L.; Chan, Tin-Yau; Liu, Yi-Tsung; Zhu, Zhaoning; Njoroge, F. George; Arasappan, Ashok; Parekh, Tejal N.; Ganguly, Ashit K.; Chen, Kevin X.; Venkatraman, Srikanth; Vaccaro, Henry A.; Pinto, Patrick A.; Santhanam, Bama; Wu, Wanli; Hendrata, Siska; Huang, Yuhua; Kemp, Scott Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita; Tamura, Susan Y.
PA Schering Corporation, USA; Corvas International, Inc.
SO PCT Int. Appl., 536 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002008244	A2	20020131	WO 2001-US22678	20010719
WO 2002008244	A3	20030619		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL,

TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2001076988	A5	20020205	AU 2001-76988	20010719
	BR 2001012540	A	20030624	BR 2001-12540	20010719
	NO 2003000272	A	20030321	NO 2003-272	20030120
PRAI	US 2000-220108P	P	20000721		
	WO 2001-US22678	W	20010719		

OS MARPAT 136:167698

AB Peptides I were prepd. wherein Y is alkyl, alkyl-aryl, heteroaryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkylheteroaryl, cycloalkyl, alkyloxy, alkylaryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy,, alkylamino, arylamino, alkylarylamino, arylamino, heteroarylamino, cycloalkylamino and heterocycloalkylamino; R1 is acyl, borate; Z is selected from O, N, CH or CR; W, Q, G, J, L, M independently maybe present or absent; W is C=O, C=S, C(=N-CN), or SO; Q is CH, N, P, alkylidene, O, amine,S, or SO; A is O, CH, alkylidene, amine, S, SO or bond; E is CH, N, alkylidene, or double bond; G is alkylidene; J is alkylidene, SO, NH, NR, O; L is CH, alkylidene, O, S or NR; M is O, NR,S, SO, alkylidene; p is 0 to 6; and R-R4 are independently selected from the group consisting of H; alkyl; alkenyl; cycloalkyl; heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, halogen; (cycloalkyl)alkyl and (heterocycloalkyl)alkyl, which have HCV protease inhibitory activity as well as methods for prepg. such compds. In another embodiment, the invention discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease. Thus peptide II was prepd. and tested as antiviral agent and NS3-serine protease inhibitors of hepatitis C virus with Ki ranges in category A = 1-100 nM; category B = 101-1,000 nM; category C > 1000 nM. Also disclosed is the use of I for the manuf. of a medicament for treating HCV, AIDS, and related disorders.

IT **394721-12-1P 394728-61-1P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 394721-12-1 CAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(3S)-6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394728-61-1 CAPLUS
CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-(3S)-6,10-dithia-2-azaspiro[4.5]decane-3-carbonyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> FIL STNGUIDE

	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	32.90	241.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.60	-2.60

16/09/200315:47Print selected from Online session

FILE 'STNGUIDE' ENTERED AT 15:43:28 ON 16 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 12, 2003 (20030912/UP).

=> d his

(FILE 'HOME' ENTERED AT 15:09:38 ON 16 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:09:47 ON 16 SEP 2003
L1 STRUCTURE UPLOADED
L2 0 S L1 EXA FULL
L3 STRUCTURE UPLOADED
L4 0 S L3 EXA FULL
L5 STRUCTURE UPLOADED
L6 0 S L5 EXA FULL
L7 STRUCTURE UPLOADED
L8 2 S L7 EXA FULL

FILE 'CAPLUS' ENTERED AT 15:24:15 ON 16 SEP 2003
L9 2 S L8

FILE 'STNGUIDE' ENTERED AT 15:43:28 ON 16 SEP 2003

=>